The EPS estimate of Seattle Genetics, Inc. (NASDAQ:SGEN) for quarter ended 2016-12-31 is $-0.32.
EPS projections 7 and 30 days ago were $-0.32 and $-0.32 respectively. Analysts projected $-0.32 and $-0.32 respectively as EPS 60 and 90 days ago. The projections shows a change of -0.03% from estimates of 7-days ago.
The EPS revisions up and down count in the preceding 7 days were 2 and 3 respectively. The count of bullish revisions in earnings in the last 1-month, 60, 90 and 120 days were 2, 2, 2 and 2.
The count of bearish revisions of EPS in the last 1-month, 60, 90 and 120 days were 3, 3, 4 and 3.
The count of EPS revisions bullish and bearish in the last 18 days were 0 and 2 respectively.
The EPS projection prior to the release of actual report for the period closed 2 is $-0.32 on basis of 8 EPS estimates. As on 2016-07-26, the reported EPS was $-0.23, showing a surprise of $0.1 or 30.3%. It showed a standard deviation of 0.03.
Quarterly Sales Estimates
The arithmetic mean of released annual sales estimates for Seattle Genetics, Inc. (NASDAQ:SGEN) is $106.915 and the median is $106.93. The estimate is calculated by 4 analysts for the fiscal 2016.
The highest annual estimate is $110 and the lowest estimate is $103.802. The standard deviation of given annual sales estimates is 2.585%.
As many as 4 and 4 analysts have increased and decreased sales estimate, respectively in last seven days. It shows a percentage change of -2.228% from the past week.
Almost 4 and 4 analysts have increased and decreased sales estimate, respectively in last one month. It shows a percentage change of -1.53% from last month.
The number of analysts who have upped and decreased their sales projections in the last one-quarter is 4 and 4 respectively. The change in the estimate from last quarter is -0.451%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...